Abstract
A limited number of studies have indicated an association between isoleucyl-tRNA synthetase 2 (IARS2) and tumorigenesis. We evaluated IARS2 protein expression in lung tumor tissues and paired non-tumor tissues. We found higher IARS2 expression in the tumor tissues, which was associated with the late Tumor and Node stages of the Tumor, Node, Metastasis staging system. Silencing IARS2 inhibited the activity of A549 and H1299 cells, resulting in G0/G1 stasis of A549 cells and mitochondrial apoptosis. IARS2 silencing was also found to inhibit NSCLC tumor growth in nude mice. Complementary DNA microarray analysis revealed 742 differentially expressed genes (507 upregulated and 235 downregulated) in IARS2-silenced A549 cells compared to controls. Ingenuity Pathway Analysis of the differential expression data suggested that multiple pathways are associated with IARS2 silencing in NSCLC cells; upstream analysis predicted the activation or inhibition of transcriptional regulators. Correlation analysis revealed that AKT and MTOR activities were significantly inhibited in IARS2-silenced cells, but were partially restored by the AKT-stimulating agent SC79. IARS2 appears to regulate lung cancer cell proliferation via the AKT/MTOR pathway. Our results help clarify the complex roles of IARS2 in tumorigenesis and suggest that it may be a novel regulator of lung cancer development.
Introduction
Lung cancer remains a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for the vast majority of cases. Despite advances in treatment, the prognosis for many patients remains poor, necessitating the discovery of new biomarkers and therapeutic targets. This study focuses on IARS2, a mitochondrial enzyme responsible for charging tRNAs with isoleucine. While traditionally viewed as housekeeping enzymes, aminoacyl-tRNA synthetases (ARSs) are increasingly recognized for their "moonlighting" roles in cell signaling and cancer progression. This research defines the specific role and molecular mechanism of IARS2 in NSCLC.
Methods
The study employed a multi-disciplinary approach combining clinical data, molecular biology, and in vivo modeling:
- Clinical Correlation: IARS2 protein expression was analyzed in 56 pairs of NSCLC tumor tissues and adjacent healthy tissues using Western Blotting.
- Gene Silencing: Lentiviral-mediated RNA interference (shRNA) was used to knock down IARS2 expression in A549 and H1299 cell lines.
- Phenotypic Assays: Impact of IARS2 loss was measured via CCK-8 assays (viability), colony formation assays, and flow cytometry (cell cycle and apoptosis).
- Transcriptomics: cDNA microarray analysis and Ingenuity Pathway Analysis (IPA) identified global gene expression changes.
- Rescue Experiments: The AKT activator SC79 was used to determine if re-activating the AKT pathway could rescue cells from IARS2 knockdown effects.
- Animal Models: Findings were validated using a nude mouse xenograft model.
Key Insights and Results
IARS2 as a Stage-Specific Marker
Analysis of clinical samples revealed that IARS2 expression is significantly elevated in tumor tissues compared to adjacent normal tissues. Furthermore, higher IARS2 expression correlated specifically with advanced T (Tumor) and N (Node) stages, suggesting IARS2 may drive the transition to more aggressive, metastatic cancer.
Phenotypic Impact of IARS2 Silencing
Silencing IARS2 significantly inhibited the proliferation and colony-forming ability of NSCLC cells. Phenotypic analysis showed that knockdown led to a significant increase in the proportion of cells arrested in the G0/G1 phase. Additionally, silencing triggered mitochondrial apoptosis, characterized by an increased Bax/Bcl-2 ratio and the activation of Caspase-3 and Caspase-9.
The AKT/MTOR Connection
Transcriptomic analysis identified 742 differentially expressed genes following IARS2 knockdown. The most significant finding was that IARS2 acts as an upstream regulator of the AKT/MTOR pathway. When IARS2 is silenced, the phosphorylation of AKT and MTOR drops significantly. The inhibitory effects on cell proliferation were partially restored when cells were treated with the AKT activator SC79, confirming that the AKT/MTOR pathway is a primary mechanism through which IARS2 exerts its oncogenic effects.
Conclusion and Future Work
This study establishes IARS2 as a potent oncogene in NSCLC that regulates cell proliferation via the AKT/MTOR pathway. While the link is clear, the exact molecular bridge—how a mitochondrial tRNA synthetase signals to cytoplasmic AKT—remains to be fully elucidated. Future work with larger clinical cohorts is needed to validate IARS2 as a diagnostic biomarker and a potential druggable target for NSCLC treatment.
Summary updated